

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on May 2, 2005

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1636  
Patent Application  
Docket No. GJE-74  
Serial No. 09/913,443

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1636  
Applicant : Jack Price  
Serial No. : 09/913,443  
Filed : August 14, 2001  
Conf. No. : 9647  
For : Transplantation of Haematopoietic Cells

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicant has not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.


J:\GJE\74\PTO\SIDS4.pto.doc/DNB/mv

05/04/2005 FHETEK11 00000034 190065 09913443

01 FC:1806 180.00 DA

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of some references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/913,443
Filing Date	August 14, 2001
First Named Inventor	Jack Price
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	GJE-74

Sheet

1

of

2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,588,692	11-18-1997	Jat et al.	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/913,443	
			Filing Date	August 14, 2001	
			First Named Inventor	Jack Price	
			Group Art Unit	1636	
			Examiner Name	Celine X. Qian	
Sheet	2	of	2	Attorney Docket Number	GJE-74

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	COGLE, C.R. <i>et al.</i> "Bone marrow transdifferentiation in brain after transplantation: a retrospective study" <i>Lancet</i> , 2004, 363(9419):1432-1437, abstract.	
	R2	DAADI, M.M. and S. WEISS "Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain" <i>J. Neuroscience</i> , 1999, 19(11):4484-4497.	
	R3	EGLITIS, M. and E. MEZEY "Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice" <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94:4080-4085.	
	R4	GOOLSBY, J. <i>et al.</i> "Hematopoietic progenitors express neural genes" <i>PNAS</i> , 2003, 100(25):14926-14931.	
	R5	HAO, H.N. <i>et al.</i> "Fetal human hematopoietic stem cells can differentiate sequentially into neural stem cells and then astrocytes in vitro" <i>J. Hematother Stem Cell Res.</i> , 2003, 12(1):23-32.	
	R6	HESS, D.C. <i>et al.</i> "Bone marrow as a source of endothelial cells and NeuN-expressing cells after stroke" <i>Stroke</i> , 2002, 33:1362-1368.	
	R7	JAT, P.S. <i>et al.</i> "Direct derivation of conditionally immortal cell lines from an H-2K <sup>b</sup> -tsA58 transgenic mouse" <i>Proc. Natl. Acad. Sci. USA</i> , 1991, 88:5096-5100.	
	R8	JAT, P. and SHARP, P. "Cell lines established by a temperature-sensitive simian virus 40 large-T-antigen gene are growth restricted at the nonpermissive temperature" <i>Mol. Cell. Biology</i> , 1989, 9(4):1672-1681.	
	R9	KOSHIZUKA, S. <i>et al.</i> "Transplanted hematopoietic stem cells from bone marrow differentiate into neural lineage cells and promote functional recovery after spinal cord injury in mice" <i>J. Neuropath. Exp. Neurology</i> , 2004, 63(1):64-72.	
	R10	PRILLER, J. "Can adult bone marrow stem cells help repair the brain?" <i>ACNR</i> , 2004, 3(6):11-13.	
	R11	PRILLER, J. <i>et al.</i> "Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment" <i>Nature Med.</i> , 2001, 7(12):1356-1361.	
	R12		
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.